Completed PHASE4 INTERVENTIONAL 4-arm NCT00823875

Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject

A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject

Sponsor: Otsuka Beijing Research Institute

Conditions Atherosclerosis Cerebral Infarction

Interventions Cilostazol + Probucol group Cilostazol group Probucol group control group

Updated 5 times since 2017 Last updated: Nov 30, 2010 Started: Mar 31, 2009 Primary completion: Dec 31, 2009 Completion: Jul 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Atherosclerosis Cerebral Infarction and is currently completed. Otsuka Beijing Research Institute leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Otsuka Beijing Research Institute

Data source: Otsuka Beijing Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China